2 weeks Ago
New AstraZeneca breast cancer drug shows 'meaningful improvement' in survivability rates By DAILY MAIL CITY & FINANCE REPORTER Updated: 17:00 EDT, 21 April 2025 e-mail View comments AstraZeneca has revealed that one of its new drugs has shown a ‘meaningful improvement’ in survivability rates in patients suffering from an aggressive form of breast cancer. The FTSE 100 pharma giant said a late-stage trial of its Enhertu treatment showed the drug demonstrated a ‘highly statistically significant’ improvement on an existing drug cocktail when it was combined with another medicine, Pertuzumab. The trial was testing Enhertu’s effectiveness against HER2-positive metastatic breast cancer.
Only 30 per cent of those diagnosed with the illness survive beyond five years. AstraZeneca said the results from the trial were the first in more than a decade to show a new medicine had been more effective across a broad range of patients at treating the illness, against the current standard of care. Breakthrough: Astrazeneca said a trial of its Enhertu treatment showed the drug demonstrated a 'highly statistically significant' improvement on an existing treatment.
RELATED ARTICLES Previous 1 Next Dollar in the eye of a storm as Trump's policies push the US...
Wall Street suffers another sharp sell-off as Trump steps up...
Share this article Share HOW THIS IS MONEY CAN HELP How to choose the best (and cheapest) stocks and shares Isa and the right DIY investing account DIY INVESTING PLATFORMS AJ Bell AJ Bell Easy investing and ready-made portfolios Learn More Learn More Hargreaves Lansdown Hargreaves Lansdown Free fund dealing and investment ideas Learn More Learn More interactive investor interactive investor Flat-fee investing from £4.99 per month Learn More Learn More Saxo Saxo Get £200 back in trading fees Learn More Learn More Trading 212 Trading 212 Free dealing and no account fee Learn More Learn More Affiliate links: If you take out a product This is Money may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting.
This does not affect our editorial independence. Compare the best investing account for you Share or comment on this article: New AstraZeneca breast cancer drug shows 'meaningful improvement' in survivability rates e-mail Add comment Some links in this article may be affiliate links. If you click on them we may earn a small commission.
That helps us fund This Is Money, and keep it free to use. We do not write articles to promote products. We do not allow any commercial relationship to affect our editorial independence.
Comments 0 Share what you think No comments have so far been submitted. Why not be the first to send us your thoughts, or debate this issue live on our message boards. Add your comment Enter your comment By posting your comment you agree to our house rules .
Submit Comment Clear Close Do you want to automatically post your MailOnline comments to your Facebook Timeline? Your comment will be posted to MailOnline as usual. No Yes Close Do you want to automatically post your MailOnline comments to your Facebook Timeline? Your comment will be posted to MailOnline as usual We will automatically post your comment and a link to the news story to your Facebook timeline at the same time it is posted on MailOnline. To do this we will link your MailOnline account with your Facebook account.
We’ll ask you to confirm this for your first post to Facebook. You can choose on each post whether you would like it to be posted to Facebook. Your details from Facebook will be used to provide you with tailored content, marketing and ads in line with our Privacy Policy .
More top stories.
